CORE Biomedicine Website, Blog & Press Pages

Pricing Book Demo

CORE Biomedicine Website, Blog & Press Pages - aVenture

CORE Biomedicine - Library

Official pages and third-party coverage in one index.

corebiomedicine.com9 items across 3 mapped pages · Crawled Sep 25, 2026

Official pages and third-party coverage in one index

Careers & Hiring

1 page

Jobs/jobs
We are currently fully staffed and have no openings at the moment. Please check back in the future.

Team

1 page

Team/team
Our team brings together leaders in drug discovery, translational biology, and clinical development — each united by the goal of delivering the next generation of precision cancer medicines.

Homepage

1 page

Homepage/
CORE Biomedicine is a preclinical-stage oncology company dedicated to innovating precision medicine therapeutics by targeting core lineage-dependent pathways in cancer.

Not yet classified

1 page

corebiomedicine.com/
CORE Biomedicine is a preclinical-stage oncology company dedicated to innovating precision medicine therapeutics by targeting core lineage-dependent pathways in cancer.

Coverage

5 items

Core Biomedicine Raises $21M Series A to Advance Precision Oncology Pipelinecitybiz.co/article/880732/core-biomedicine-raises-21m-series-a-to-advance-precision-oncology-pipeline/
Core Biomedicine raises $21 million in Series A financing and secures a Japanese government grant to advance its precision oncology drug pipeline. The pipeline targets lineage-dependent cancer pathways.
Jul 2026 · citybizNews article
CORE Biomedicine Secures $21 Million Series A and Eisai Licensing Deal to Advance Lineage-Based Precision Oncology Pipelinetrial.medpath.com/news/core-biomedicine-secures-21-million-series-a-and-eisai-licensing-deal-to-advance-lineage-based-precision-oncology-pipeline
CORE Biomedicine completes a $21 million Series A co-led by UTokyo Innovation Platform and Elikon Venture and signs an exclusive licensing agreement with Eisai. The financing and deal are intended to advance the company's lineage-based precision oncology pipeline.
Jul 2026 · MedPathNews article
CORE Biomedicine Secures $21 Million Series A Venture Financingbiospace.com/press-releases/core-biomedicine-secures-21-million-series-a-venture-financing-and-receives-amed-grant-award-to-advance-novel-cancer-therapeutics
CORE Biomedicine secures $21 million in Series A financing and an AMED grant award to advance novel cancer therapeutics beyond genomics. The biotechnology company describes its approach as lineage-based precision oncology therapeutics.
Jul 2026 · BioSpaceNews article
CORE Biomedicine Secures $21 Million Series A Venture Financing and Receives AMED Grant Award to Advance Novel Cancer Therapeuticsprnewswire.com/news-releases/core-biomedicine-secures-21-million-series-a-venture-financing-and-receives-amed-grant-award-to-advance-novel-cancer-therapeutics-302836054.html
CORE Biomedicine secures $21 million in Series A venture financing to advance its cancer therapeutics program. The round is co-led by UTokyo Innovation Platform and Elikon Venture, with broad participation from global investors, and the company also receives an AMED grant for its lineage-based precision oncology therapeutics.
Jul 2026 · PR NewswireNews article